Open-Label Extension Study to Provide Access to ATH434 in Patients with Multiple System Atrophy

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-524317-88-00

Enrollment

Registered

2026-05-13

Start date

Unknown

Completion date

Unknown

Last updated

2026-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple System Atrophy

Brief summary

Assessment of long term safety and tolerability based on incidence and severity of AEs and SAEs, changes in laboratory and vital sign parameters including orthostatic measures, exposure to ATH434, treatment discontinuations due to adverse events, and deaths.

Interventions

DRUGATH434-DP2

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Assessment of long term safety and tolerability based on incidence and severity of AEs and SAEs, changes in laboratory and vital sign parameters including orthostatic measures, exposure to ATH434, treatment discontinuations due to adverse events, and deaths.	—

Outcome results

None listed

Source: EU CTIS · Data processed: May 14, 2026